|
Allos
Therapeutics, Inc. (NASDAQ: ALTH)
is a biopharmaceutical company focused on developing and
commercializing innovative small molecule drugs for the treatment of cancer. The Company's
lead product candidate, pralatrexate (PDX) is a novel antifolate currently
under evaluation in a pivotal Phase 2 (PROPEL) trial
in patients with relapsed or refractory peripheral T-cell lymphoma.
The PROPEL trial is being conducted under an agreement reached with
the U.S. Food and Drug Administration under its special protocol assessment, or SPA process.
The Company is also investigating pralatrexate in patients
with non-small cell lung cancer, bladder cancer and
a range of lymphoma sub-types. The Company's other product candidate
is RH1, a targeted chemotherapeutic agent currently being evaluated in a Phase
1 trial in patients with advanced solid tumors or
non-Hodgkin’s lymphoma (NHL). Allos currently retains exclusive worldwide rights to
pralatrexate and RH1 for all indications. more
Click
here to learn more about pralatrexate
Click
here to learn more about RH1
|